X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ORCHID PHARMA LTD - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ORCHID PHARMA LTD IPCA LABS/
ORCHID PHARMA LTD
 
P/E (TTM) x 27.5 -0.6 - View Chart
P/BV x 2.1 0.5 462.6% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 IPCA LABS   ORCHID PHARMA LTD
EQUITY SHARE DATA
    IPCA LABS
Mar-17
ORCHID PHARMA LTD
Sep-13
IPCA LABS/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs643194 331.4%   
Low Rs50335 1,436.6%   
Sales per share (Unadj.) Rs254.4276.5 92.0%  
Earnings per share (Unadj.) Rs16.1-79.2 -20.3%  
Cash flow per share (Unadj.) Rs29.8-43.5 -68.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.653.9 360.7%  
Shares outstanding (eoy) m126.2070.45 179.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.30.4 543.7%   
Avg P/E ratio x35.7-1.4 -2,466.3%  
P/CF ratio (eoy) x19.2-2.6 -730.2%  
Price / Book Value ratio x2.92.1 138.7%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,3008,067 896.3%   
No. of employees `00013.32.8 475.1%   
Total wages/salary Rs m6,9602,527 275.4%   
Avg. sales/employee Rs Th2,413.56,956.1 34.7%   
Avg. wages/employee Rs Th523.2902.5 58.0%   
Avg. net profit/employee Rs Th152.4-1,993.0 -7.6%   
INCOME DATA
Net Sales Rs m32,10619,477 164.8%  
Other income Rs m226407 55.4%   
Total revenues Rs m32,33219,884 162.6%   
Gross profit Rs m4,4481,103 403.4%  
Depreciation Rs m1,7302,519 68.7%   
Interest Rs m2415,227 4.6%   
Profit before tax Rs m2,703-6,236 -43.3%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m675-125 -539.3%   
Profit after tax Rs m2,028-5,580 -36.3%  
Gross profit margin %13.95.7 244.7%  
Effective tax rate %25.02.0 1,244.1%   
Net profit margin %6.3-28.7 -22.0%  
BALANCE SHEET DATA
Current assets Rs m17,34011,014 157.4%   
Current liabilities Rs m9,55932,060 29.8%   
Net working cap to sales %24.2-108.1 -22.4%  
Current ratio x1.80.3 528.0%  
Inventory Days Days10095 105.7%  
Debtors Days Days5734 169.4%  
Net fixed assets Rs m20,77929,440 70.6%   
Share capital Rs m252705 35.8%   
"Free" reserves Rs m24,4992,043 1,199.4%   
Net worth Rs m24,5533,800 646.1%   
Long term debt Rs m3,5179,018 39.0%   
Total assets Rs m39,59546,510 85.1%  
Interest coverage x12.2-0.2 -6,330.7%   
Debt to equity ratio x0.12.4 6.0%  
Sales to assets ratio x0.80.4 193.6%   
Return on assets %5.7-0.8 -753.9%  
Return on equity %8.3-146.9 -5.6%  
Return on capital %10.5-3.7 -280.8%  
Exports to sales %48.637.9 128.4%   
Imports to sales %14.222.6 62.9%   
Exports (fob) Rs m15,6177,378 211.7%   
Imports (cif) Rs m4,5714,406 103.7%   
Fx inflow Rs m15,6177,513 207.9%   
Fx outflow Rs m5,8285,649 103.2%   
Net fx Rs m9,7901,865 525.1%   
CASH FLOW
From Operations Rs m2,7641,682 164.4%  
From Investments Rs m-1,432-9,860 14.5%  
From Financial Activity Rs m-1,5916,644 -24.0%  
Net Cashflow Rs m-259-1,535 16.9%  

Share Holding

Indian Promoters % 45.9 32.3 142.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 4.6 247.8%  
FIIs % 25.3 3.3 766.7%  
ADR/GDR % 0.0 4.6 -  
Free float % 17.4 55.3 31.5%  
Shareholders   36,892 84,811 43.5%  
Pledged promoter(s) holding % 2.1 54.9 3.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Share Buybacks, GST Cess on Motor Vehicles, and Top Stocks in Focus Today(Pre-Open)

Indian share markets witnessed buying interest on Wednesday and finished their session in the green for the second straight session. Heavy buying was seen in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 23, 2017 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - BIOCON LTD COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS